Serán BioScience, LLC, a prominent player in drug development, has announced the completion of two buildings and the initiation of construction on a third for its new 100,000 ft² commercial manufacturing campus in Bend, Oregon. This expansion includes a dedicated 50,000 ft² manufacturing facility alongside an additional 50,000 ft² space for specialized packaging and supply chain operations, marking a significant advancement in Serán’s capabilities to support the entire lifecycle of small-molecule therapeutics.
The expansion is bolstered by a recent investment from Bain Capital Life Sciences, alongside ongoing support from Vivo Capital. The new facility is designed to meet the growing demand for complex oral solid dosage forms, allowing Serán to deliver comprehensive, end-to-end solutions that adhere to global regulatory standards. The site is equipped for advanced processes such as spray drying and particle engineering, ensuring high-quality production of non-sterile solid dose products.
Dan Smithey, CEO of Serán BioScience, emphasized that the investment aims to address the evolving needs of pharmaceutical companies for scalable manufacturing solutions that enhance clinical performance and expedite market entry. The new campus, strategically located near their existing operations, will integrate seamlessly with current clinical development efforts, further solidifying Serán’s role as a vital partner for both emerging biotech firms and established pharmaceutical organizations.
Open the full market picture for your next decision →
